← Back to Patent Explorer
US4678808A Expired / Lapsed US ⏱️ 0.0 years remaining

Rapid acting intravenous emulsions of omega-3 fatty acid esters

Assignee: Baxter International Inc
•
Filing: 1985-10-15
•
Granted: 1987-07-07
•
Expires: 2005-10-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Described are lipid emulsions of marine oils comprising high concentrations of omega-3-fatty acid esters and low concentrations of free fatty acids for intraveneous administration for the treatment of thrombic disease states. More specifically, a lipid emulsion for parenternal use is provided comprising an emulsifier, water and a marine oil comprising an omega-3-fatty ester in which the concentration of the free fatty acid in the emulsion is below about 5 meq/l.

Inventors

  • 👤 Michael V. Ward
  • 👤 Richard Cotter

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 12:43
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/56; A61K35/60; A61K31/00; A61K31/21; A61K31/215; A61K31/22; A61K31/23; A61P; A61P7/00; A61P7/02

Claims Analysis

Total Claims: 20
Claim 1
Independent Claim 52 words
A lipid emulsion for parenteral use comprising an emulsifier, water and a marine oil comprising at least one omega 3 fatty acid ester wherein the concentration of free fatty acid in the emulsion is below about 5 meq/l and wherein the concentration of marine oil is between about 5% to about 50%.
Claim 2
Dependent Claim 52 words
A lipid emulsion for parenteral use comprising an emulsifier, water and a marine oil comprising at least one omega 3 fatty acid ester wherein the concentration of free fatty acid in the emulsion is below about 5 meq/l and wherein the concentration of marine oil is between about 5% to about 50%.
Claim 3
Dependent Claim 26 words
The emulsion of claim 1 wherein the marine oil contains at least 30% by weight of a combination of esters of eicosapentaenoic acid and docosahexaenoic acid.
Claim 4
Dependent Claim 25 words
The emulsion of claim 1 wherein the concentration of the ester of eicosapentaenoic acid in the marine oil is between about 10% to about 100%.
Claim 5
Dependent Claim 31 words
The emulsion of claim 1 wherein the emulsifier is selected from the group consisting of egg yolk phosphatide, soy phosphatide, purified egg yolk lecithin, purified soy lecithin and other purified phospholipids.
Claim 6
Dependent Claim 32 words
The emulsion of claim 1 wherein the emulsifier concentration is either 1.2%, 0.6% or 0.4%, the latter two being the most effective in producing rapid bioavailability of eicosapentaenoic acid and docosahexaenoic acid.
Claim 7
Dependent Claim 24 words
The emulsion of claim 6 wherein the osmotic agent is selected from the group containing glycerin, glucose and sucrose, sorbitol, physiologically aceptable sodium phosphate.
Claim 8
Dependent Claim 10 words
The emulsion of claim 1 further comprising an osmotic agent.
Claim 9
Dependent Claim 20 words
The emulsion of claim 1 in which essentially all lipid particles present have a diameter of less than 0.5 microns.
Claim 10
Dependent Claim 13 words
The emulsion of claim 1 having an osmolarity of 280 to 300 milliosmoles.
Claim 11
Dependent Claim 22 words
The emulsion of claim 1 wherein the marine oil is selected from the group comprising menhaden oil, salmon oil and sardine oil.
Claim 12
Dependent Claim 76 words
A lipid emulsion for intravenous administration use and effective for inhibiting platelet function comprising from 0.2 to 1.5% of an emulsifier selected from the group consisting of egg yolk phosphatide, soy phosphatide, purified egg yolk lecithin, and purified soil lecithin, from 5 to 50% of a marine oil comprising at least 30% of omega-3 fatty acid esters of glycerol, and water, essentially all lipid particles in the emulsion having a diameter of less than 0.75 microns.
Claim 13
Dependent Claim 76 words
A lipid emulsion for intravenous administration use and effective for inhibiting platelet function comprising from 0.2 to 1.5% of an emulsifier selected from the group consisting of egg yolk phosphatide, soy phosphatide, purified egg yolk lecithin, and purified soil lecithin, from 5 to 50% of a marine oil comprising at least 30% of omega-3 fatty acid esters of glycerol, and water, essentially all lipid particles in the emulsion having a diameter of less than 0.75 microns.
Claim 14
Dependent Claim 29 words
The lipid emulsion of claim 11 in which the marine oil contains at least 30% by weight of a combination of glycerol esters of eicosapentaenoic acid and docosahexaenoic acid.
Claim 15
Dependent Claim 19 words
The lipid emulsion of claim 12 in which the concentration of marine oil present is from 10 to 20%.
Claim 16
Dependent Claim 30 words
The lipid emulsion of claim 13 in which an osmotic agent is present selected from the group consisting of glycerin, glucose, sucrose, sorbitol, physiologically acceptable proteins, and sodium acid phosphate.
Claim 17
Dependent Claim 22 words
The lipid emulsion of claim 14 in which sufficient osmotic agent is present to provide an osmolarity of 280 to 300 milliosmoles.
Claim 18
Dependent Claim 18 words
The lipid emulsion of claim 15 in which less than 5 meq/l of free fatty acids are present.
Claim 19
Independent Claim 57 words
A method of rapidly inhibiting platelet function in an animal said method comprising intravenously administering to said animal a platelet inhibiting effective amount of a lipid emulsion comprising an emulsifier, water and a marine oil comprising at least one omega-3 fatty ester wherein the concentration of free fatty acid in the emulsion is below about 5 meq/l.
Claim 20
Independent Claim 57 words
A method of rapidly inhibiting platelet function in an animal said method comprising intravenously administering to said animal a platelet inhibiting effective amount of a lipid emulsion comprising an emulsifier, water and a marine oil comprising at least one omega-3 fatty ester wherein the concentration of free fatty acid in the emulsion is below about 5 meq/l.

References Cited (Backward Citations)

US4513008A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-07-06 1991-01-05 1991-07-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-07-06 1995-01-05 1995-07-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-07-06 1999-01-05 1999-07-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag